Literature DB >> 23708780

Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway.

Dae Hyung Lee1, In-Hye Lim, Eon-Gi Sung, Joo-Young Kim, In-Hwan Song, Yoon Ki Park, Tae-Jin Lee.   

Abstract

Withaferin A (Wit A), a steroidal lactone isolated from Withania somnifera, exhibits anti-inflammatory, immuno-modulatory and anti-angiogenic properties and antitumor activities. In the present study, we investigated the effects of Wit A on protease-mediated invasiveness of the human metastatic cancer cell lines Caski and SK-Hep1. We found that treatment with Wit A resulted in marked inhibition of the TGF‑β‑induced increase in expression and activity of matrix metalloproteinase (MMP)‑9 in Caski cell line. These effects of Wit A were dose-dependent and showed a correlation with suppression of MMP‑9 mRNA expression levels. Treatment with Wit A resulted in an ~1.6-fold induction of MMP-9 promoter activity, which was also suppressed by treatment with Wit A in Caski cells. We found that treatment with Wit A resulted in inhibition of TGF‑β‑induced phosphorylation of Akt, which was involved in the downregulation of expression of MMP-9 at the protein level. Introduction with constitutively active (CA)‑Akt resulted in a partial increase in the secretion of TGF-β-induced MMP-9 blocked by treatment with Wit A in Caski cells. According to these results, Wit A may inhibit the invasive and migratory abilities of Caski cells through a reduction in MMP-9 expression through suppression of the pAkt signaling pathway. These findings indicate that use of Wit A may be an effective strategy for control of metastasis and invasiveness of tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708780     DOI: 10.3892/or.2013.2487

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

1.  Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis.

Authors:  Green Kim; Tae-Hyoun Kim; Eun-Ha Hwang; Kyu-Tae Chang; Jung Joo Hong; Jong-Hwan Park
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

Review 2.  Broad-spectrum antitumor properties of Withaferin A: a proteomic perspective.

Authors:  Martin Dom; Wim Vanden Berghe; Xaveer Van Ostade
Journal:  RSC Med Chem       Date:  2019-12-16

Review 3.  Susceptibility of cytoskeletal-associated proteins for tumor progression.

Authors:  Abiola Abdulrahman Ayanlaja; Xiaoliang Hong; Bo Cheng; Han Zhou; Kouminin Kanwore; Piniel Alphayo-Kambey; Lin Zhang; Chuanxi Tang; Muinat Moronke Adeyanju; Dianshuai Gao
Journal:  Cell Mol Life Sci       Date:  2021-12-29       Impact factor: 9.261

4.  Low Concentration of Withaferin a Inhibits Oxidative Stress-Mediated Migration and Invasion in Oral Cancer Cells.

Authors:  Tzu-Jung Yu; Jen-Yang Tang; Fu Ou-Yang; Yen-Yun Wang; Shyng-Shiou F Yuan; Kevin Tseng; Li-Ching Lin; Hsueh-Wei Chang
Journal:  Biomolecules       Date:  2020-05-17

5.  Combination of Withaferin-A and CAPE Provides Superior Anticancer Potency: Bioinformatics and Experimental Evidence to Their Molecular Targets and Mechanism of Action.

Authors:  Anissa Nofita Sari; Priyanshu Bhargava; Jaspreet Kaur Dhanjal; Jayarani F Putri; Navaneethan Radhakrishnan; Seyad Shefrin; Yoshiyuki Ishida; Keiji Terao; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  Cancers (Basel)       Date:  2020-05-05       Impact factor: 6.639

6.  Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.

Authors:  Vidhi Malik; Vipul Kumar; Sunil C Kaul; Renu Wadhwa; Durai Sundar
Journal:  Biomolecules       Date:  2021-01-26

Review 7.  Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin.

Authors:  Devesh Tewari; Anu Priya; Anusha Bishayee; Anupam Bishayee
Journal:  Clin Transl Med       Date:  2022-04

Review 8.  Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action.

Authors:  In-Chul Lee; Bu Young Choi
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

Review 9.  Natural Withanolides in the Treatment of Chronic Diseases.

Authors:  Peter T White; Chitra Subramanian; Hashim F Motiwala; Mark S Cohen
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 10.  Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics.

Authors:  Vivek K Kashyap; Godwin Peasah-Darkwah; Anupam Dhasmana; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  Pharmaceutics       Date:  2022-03-10       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.